PMID- 29503557
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220316
IS  - 1176-6336 (Print)
IS  - 1178-203X (Electronic)
IS  - 1176-6336 (Linking)
VI  - 14
DP  - 2018
TI  - The clinical course of symptomatic deep vein thrombosis after 3 months of 
      anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K 
      antagonist.
PG  - 377-383
LID - 10.2147/TCRM.S153517 [doi]
AB  - BACKGROUND: For the management of venous thromboembolism (VTE), providing 
      anticoagulant therapy within the therapeutic range has been a major challenge, as 
      conventional therapy with unfractionated heparin (UFH) and vitamin K antagonist 
      (VKA) requires frequent laboratory monitoring and dose adjustment. Recently, 
      fondaparinux and edoxaban are being used as beneficial alternatives to UFH and 
      VKA. METHODS: We evaluated the clinical course of symptomatic deep vein 
      thrombosis (DVT) in patients who received the 3-month anticoagulation therapy 
      with fondaparinux/edoxaban (Group A; n=40) in comparison with the findings from 
      our previous experience of patients who received the fondaparinux/VKA combination 
      (Group B; n=33). RESULTS: In both Groups A and B, serum D-dimer was significantly 
      improved after treatment (p<0.001). The thrombus volume assessed by quantitative 
      ultrasound thrombosis (QUT) score was significantly reduced in both groups 
      (p<0.001). There was no difference in the proportion of patients who were 
      normalized (ie, disappearance of DVT) between the groups, although Group A had 
      significantly more patients who were normalized or improved (ie, disappearance 
      and reduction of DVT) (p<0.001). No bleeding event was observed in either group. 
      However, in one patient in Group B, worsening of DVT and development of 
      symptomatic PE were observed. CONCLUSION: Fondaparinux/edoxaban therapy is as 
      effective as fondaparinux/VKA. This treatment has the possible advantage in 
      thrombus regression. This would be a beneficial therapeutic option for both 
      patients and physicians.
FAU - Shimizu, Kazuhiro
AU  - Shimizu K
AD  - Department of Internal Medicine, Toho University Sakura Medical Center, Sakura 
      City, Chiba, Japan.
FAU - Iiduka, Takuo
AU  - Iiduka T
AD  - Department of Internal Medicine, Toho University Sakura Medical Center, Sakura 
      City, Chiba, Japan.
FAU - Sato, Shuji
AU  - Sato S
AD  - Department of Internal Medicine, Toho University Sakura Medical Center, Sakura 
      City, Chiba, Japan.
FAU - Kiyokawa, Hajime
AU  - Kiyokawa H
AD  - Department of Internal Medicine, Toho University Sakura Medical Center, Sakura 
      City, Chiba, Japan.
FAU - Nakagami, Takahiro
AU  - Nakagami T
AD  - Department of Internal Medicine, Toho University Sakura Medical Center, Sakura 
      City, Chiba, Japan.
FAU - Mikamo, Hiroshi
AU  - Mikamo H
AD  - Department of Internal Medicine, Toho University Sakura Medical Center, Sakura 
      City, Chiba, Japan.
FAU - Kawazoe, Masayo
AU  - Kawazoe M
AD  - Department of Internal Medicine, Toho University Sakura Medical Center, Sakura 
      City, Chiba, Japan.
FAU - Takahashi, Mao
AU  - Takahashi M
AD  - Department of Internal Medicine, Toho University Sakura Medical Center, Sakura 
      City, Chiba, Japan.
FAU - Noro, Mahito
AU  - Noro M
AD  - Department of Internal Medicine, Toho University Sakura Medical Center, Sakura 
      City, Chiba, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180223
PL  - New Zealand
TA  - Ther Clin Risk Manag
JT  - Therapeutics and clinical risk management
JID - 101253281
PMC - PMC5827747
OTO - NOTNLM
OT  - FXa inhibitors
OT  - anticoagulant therapy
OT  - deep vein thrombosis
OT  - quantitative ultrasound thrombosis score
OT  - venous thromboembolism
COIS- Disclosure K Shimizu has received honoraria for oral presentations from Bayer 
      Yakuhin and Daiichi Sankyo. The other authors report no conflicts of interest in 
      this work.
EDAT- 2018/03/06 06:00
MHDA- 2018/03/06 06:01
PMCR- 2018/02/23
CRDT- 2018/03/06 06:00
PHST- 2018/03/06 06:00 [entrez]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/03/06 06:01 [medline]
PHST- 2018/02/23 00:00 [pmc-release]
AID - tcrm-14-377 [pii]
AID - 10.2147/TCRM.S153517 [doi]
PST - epublish
SO  - Ther Clin Risk Manag. 2018 Feb 23;14:377-383. doi: 10.2147/TCRM.S153517. 
      eCollection 2018.